Caribou Biosciences (CRBU) Equity Average (2020 - 2025)
Historic Equity Average for Caribou Biosciences (CRBU) over the last 6 years, with Q3 2025 value amounting to $154.0 million.
- Caribou Biosciences' Equity Average fell 4794.76% to $154.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $154.0 million, marking a year-over-year decrease of 4794.76%. This contributed to the annual value of $310.7 million for FY2024, which is 716.0% down from last year.
- Per Caribou Biosciences' latest filing, its Equity Average stood at $154.0 million for Q3 2025, which was down 4794.76% from $191.7 million recorded in Q2 2025.
- Over the past 5 years, Caribou Biosciences' Equity Average peaked at $396.1 million during Q4 2021, and registered a low of -$41.7 million during Q2 2021.
- Moreover, its 5-year median value for Equity Average was $295.8 million (2024), whereas its average is $263.1 million.
- In the last 5 years, Caribou Biosciences' Equity Average surged by 249788.92% in 2021 and then plummeted by 4794.76% in 2025.
- Over the past 5 years, Caribou Biosciences' Equity Average (Quarter) stood at $396.1 million in 2021, then decreased by 21.11% to $312.5 million in 2022, then increased by 22.67% to $383.3 million in 2023, then plummeted by 30.33% to $267.1 million in 2024, then plummeted by 42.34% to $154.0 million in 2025.
- Its Equity Average stands at $154.0 million for Q3 2025, versus $191.7 million for Q2 2025 and $235.1 million for Q1 2025.